Title: Oncologist, Professor of Molecular and Cell Biology
Company: SUNY Downstate Medical Center
Location: Brooklyn, New York, United States
Dr. Christopher Stephen Lange, Oncologist and Professor of Molecular and Cell Biology at SUNY Downstate Medical Center, has been recognized by Marquis Who’s Who Top Scientists for dedication, achievements, and leadership in medical research and education.
Renowned for his contributions to oncology and biology, Dr. Lange utilizes nearly 60 years of experience in a variety of positions at SUNY Downstate Medical Center and in his community. He has served the school as the associate chair of the Department of Radiation Oncology since 2010, a professor of molecular and cell biology at the School of Graduate Studies since 1992, and a professor and director of the Radiobiological Division of the Department of Radiation Oncology since 1980. Civically, Dr. Lange maintains his roles as an honorary consultant at the Holy Cross Oncology Center in Poland, an appointed science advisory for the New York State Assembly of the 13th and 16th District, a grantee of the United States Department of Energy, and the chapter treasurer of Sigma Xi.
Dr. Lange’s primary research focuses on advancing his fields, and is noted for his studies on topics such as the cellular basis of organismal radiation lethality and the cellular theory of aging. Some of his most notable accomplishments include being the first to invent visualization of a solid tumor cancer stem cell niche, discovering a mechanism of anterior-posterior polarity control during regeneration in planarians and higher animals, demonstrating DNA double-strand break repair in mammalian cells, the fact that the initial slope and shoulder of the survival curve for reproductive integrity is due to repair processes, and the fact that only 1-2 percent of cells selected as breast cancer stem cells by biomarker combinations are CSCs. Looking to the future, Dr. Lange hopes to get donors or investors for his patented technology, Hybrid Spheroid Assay, which will help patients with solid tumors and allow drug companies focusing on anti-cancer drugs to eliminate 85 percent of the clinical trials that fail. He is also scheduled to give a keynote lecture at Euro Cancer 2018 in Rome, Italy.
For more:
Contact Dr. Lange
